On May 8, 2023, the US Supreme Court extended a temporary order allowing nationwide access to mail-order mifepristone, an abortion medication, until at least May 14. This decision follows a previous ruling by the US Court of Appeals for the Fifth Circuit in Louisiana that sought to ban the mail distribution of the drug. Justice Samuel Alito granted a stay on the ban, responding to an emergency appeal from two manufacturers of mifepristone. Louisiana's lawsuit against the US Food and Drug Administration (FDA) argues that the agency's rules permitting remote prescriptions conflict with the state's abortion ban. However, the Supreme Court ruled that Louisiana lacks standing to challenge mail-order abortion, indicating that the case will return to the Fifth Circuit for further consideration. The implications of this case could affect the entire pharmaceutical industry, as it raises questions about a single state's ability to regulate medications across the nation, which traditionally falls under the FDA's jurisdiction. Meanwhile, abortion providers are preparing to offer alternative medication regimens, such as misoprostol, which, while effective, may result in increased discomfort for patients.